

Charlene M Fares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5747529/publications.pdf>

Version: 2024-02-01

9
papers

520
citations

1684188

5
h-index

1872680

6
g-index

9
all docs

9
docs citations

9
times ranked

1156
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	3.8	459
2	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nature Cancer, 2020, 1, 1167-1175.	13.2	22
3	Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	14
4	Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors. Modern Pathology, 2020, 33, 2001-2010.	5.5	13
5	Biomarkers that may predict response to immunotherapy in ovarian malignancies. Current Opinion in Obstetrics and Gynecology, 2020, 32, 84-90.	2.0	8
6	Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report. Journal of Medical Case Reports, 2021, 15, 216.	0.8	3
7	Homologous recombination deficiency and molecular subtype are associated with immunogenicity in ovarian cancer. Biomarkers in Medicine, 2022, 16, 771-782.	1.4	1
8	Association of homologous recombination deficiency in ovarian cancer with neoantigen load and expression of immune checkpoints.. Journal of Clinical Oncology, 2021, 39, 5536-5536.	1.6	0
9	Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism.. Journal of Clinical Oncology, 2020, 38, 3083-3083.	1.6	0